UBS AM
ADMS

UBS AM’s Adamas Pharmaceuticals ADMS Stock Holding History

UBS AM’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,455
Closed -$95.7K – 2894
2019
Q1 		$95.7K Sell
13,455
-96,706
-88% -$870K ﹤0.01% 2567
2018
Q4 		$941K Sell
110,161
-148,132
-57% -$1.93M ﹤0.01% 1783
2018
Q3 		$5.17M Buy
258,293
+50,319
+24% +$1.18M ﹤0.01% 1133
2018
Q2 		$5.37M Buy
207,974
+20,495
+11% +$568K ﹤0.01% 1128
2018
Q1 		$4.48M Sell
187,479
-9,619
-5% -$303K ﹤0.01% 1188
2017
Q4 		$6.68M Buy
+197,098
New +$5.5M 0.01% 1019
2016
Q3 		– Sell
-17,110
Closed -$259K – 2608
2016
Q2 		$259K Sell
17,110
-12,171
-42% -$201K ﹤0.01% 2297
2016
Q1 		$423K Buy
29,281
+13,115
+81% +$221K ﹤0.01% 2014
2015
Q4 		$458K Sell
16,166
-4,674
-22% -$78.7K ﹤0.01% 2099
2015
Q3 		$349K Sell
20,840
-1,533
-7% -$34.9K ﹤0.01% 2207
2015
Q2 		$587K Buy
+22,373
New +$435K ﹤0.01% 1981

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

UBS AM's ADMS Position: Q2 2019 in Review

UBS AM sold out of Adamas Pharmaceuticals (ADMS) in Q2 2019, closing a stake of 13,455 shares — an estimated $95.7K sold.

UBS AM first reported a position in ADMS in Q2 2015 and held it in 11 quarters. The position peaked at $6.68M in Q4 2017. 78 funds tracked by Wall St. Rank hold ADMS as of Q2 2019.

  • UBS AM reported no remaining Adamas Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • UBS AM sold 13,455 Adamas Pharmaceuticals shares in Q2 2019, an estimated $95.7K.
  • UBS AM first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 11 quarters.
  • UBS AM's Adamas Pharmaceuticals position peaked at $6.68M in Q4 2017.
  • 78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2019.

Based on UBS AM's 13F filing for Q2 2019, filed 15 Aug 2019.